1652 Stock Overview
An investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Fusen Pharmaceutical Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.97 |
52 Week High | HK$1.60 |
52 Week Low | HK$0.76 |
Beta | 0.23 |
11 Month Change | -18.49% |
3 Month Change | 7.78% |
1 Year Change | -24.22% |
33 Year Change | -69.11% |
5 Year Change | -68.91% |
Change since IPO | -61.81% |
Recent News & Updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Recent updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Shareholder Returns
1652 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -11.8% | -1.7% | -1.0% |
1Y | -24.2% | -7.7% | 0.7% |
Return vs Industry: 1652 underperformed the Hong Kong Pharmaceuticals industry which returned -7.7% over the past year.
Return vs Market: 1652 underperformed the Hong Kong Market which returned 0.7% over the past year.
Price Volatility
1652 volatility | |
---|---|
1652 Average Weekly Movement | 5.5% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 7.0% |
10% most volatile stocks in HK Market | 14.9% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1652 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1652's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 1,148 | Dudu Cao | www.fusenyy.com |
Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products.
Fusen Pharmaceutical Company Limited Fundamentals Summary
1652 fundamental statistics | |
---|---|
Market cap | HK$717.12m |
Earnings (TTM) | -HK$38.99m |
Revenue (TTM) | HK$607.85m |
1.2x
P/S Ratio-18.4x
P/E RatioIs 1652 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1652 income statement (TTM) | |
---|---|
Revenue | CN¥565.61m |
Cost of Revenue | CN¥266.10m |
Gross Profit | CN¥299.51m |
Other Expenses | CN¥335.78m |
Earnings | -CN¥36.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.049 |
Gross Margin | 52.95% |
Net Profit Margin | -6.41% |
Debt/Equity Ratio | 61.7% |
How did 1652 perform over the long term?
See historical performance and comparison